Kimberly Tobin
Adult Health · Pottstown, PANPI 1104192699
Payments from drug & device makers
Across 171 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$701
- Lilly USA, LLC$463
- AbbVie$436
- Novo Nordisk$408
- Pfizer$294
- GSK$260
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $701 |
| Lilly USA, LLC | 19 | $463 |
| AbbVie | 24 | $436 |
| Novo Nordisk | 20 | $408 |
| Pfizer | 10 | $294 |
| GSK | 13 | $260 |
| Abbott | 11 | $242 |
| Boehringer Ingelheim | 8 | $156 |
| Bayer | 2 | $139 |
| Biohaven Pharmaceuticals, Inc. | 1 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $114 |
| Merck | 6 | $109 |
| Novartis | 5 | $108 |
| Intercept Pharmaceuticals, Inc. | 1 | $100 |
| Astellas Pharma US Inc | 3 | $87 |
| Exact Sciences | 3 | $77 |
| Amgen | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Tolmar, Inc. | 2 | $31 |
| Insulet Corporation | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$243
- BREZTRI$125
- Kerendia$122
- MOUNJARO$118
How this compares
$4,090 in reported general payments places this provider in the 85th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $91,773 |
| OzempicSemaglutide | 50 | $78,639 |
| FarxigaDapagliflozin Propanediol | 47 | $47,062 |
| EliquisApixaban | 37 | $38,241 |
| XareltoRivaroxaban | 19 | $25,466 |
| MounjaroTirzepatide | 23 | $23,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,602 |
| MyrbetriqMirabegron | 22 | $12,054 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $10,305 |
| VascepaIcosapent Ethyl | 11 | $7,885 |
| LinzessLinaclotide | 11 | $7,812 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,776 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $5,464 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,383 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $156 | $91,77363 claims |
| Novo NordiskOzempic | $408 | $78,63950 claims |
| AstraZenecaFarxiga | $701 | $47,06247 claims |
| PfizerEliquis | $294 | $38,24137 claims |
| Lilly USA, LLCMounjaro | $463 | $23,01723 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $260 | $19,37834 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $12,05422 claims |
| AbbVieLinzess, Synthroid | $436 | $9,06233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Pottstown
- Krista FerrariPottstown$10K
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Jennifer MondilloSchwenksville$396K
- Elizabeth FaustDouglassville$356K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Lauren MassimoPhiladelphia$139K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.